The demand for Anti-Diabetes Drugs in Turkey has been on the rise in recent years.
Customer preferences: Customers in Turkey prefer to use oral anti-diabetes drugs as a first-line treatment option. This is due to the convenience of taking pills compared to injections, and the availability of a wide range of oral drugs in the market. Additionally, customers prefer drugs that have fewer side effects and are affordable.
Trends in the market: The Anti-Diabetes Drugs market in Turkey has been experiencing a shift towards the use of newer drugs such as DPP-4 inhibitors and GLP-1 receptor agonists. This is due to their effectiveness in controlling blood sugar levels and their lower risk of hypoglycemia compared to older drugs such as sulfonylureas. Additionally, there has been an increase in the use of combination therapies that involve the use of multiple drugs to achieve better glycemic control.
Local special circumstances: Turkey has a high prevalence of diabetes, with an estimated 13.7% of the population living with the disease. This has led to an increased demand for anti-diabetes drugs in the country. Additionally, the Turkish government provides free healthcare to its citizens, which has made it easier for people living with diabetes to access treatment.
Underlying macroeconomic factors: The Turkish economy has been growing steadily in recent years, which has led to an increase in disposable income among the population. This has made it easier for people to afford anti-diabetes drugs, which has contributed to the growth of the market. Additionally, the Turkish government has been investing heavily in the healthcare sector, which has led to the development of better healthcare infrastructure and the availability of newer drugs in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
